Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation

被引:38
作者
Gao, Jing [1 ]
Li, Yan-Yan [1 ]
Sun, Ping-Nai [1 ]
Shen, Lin [1 ]
机构
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept GI Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
关键词
DNA mutational analysis; KRAS; Mutation; Dideoxy sequencing; KRAS StripAssay; Pyrosequencing; GROWTH-FACTOR RECEPTOR; K-RAS MUTATIONS; ADVANCED COLORECTAL-CANCER; CODON-13; MUTATIONS; HUMAN-COLON; CETUXIMAB; FREQUENCY; TUMORS;
D O I
10.3748/wjg.v16.i38.4858
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To compare the differences between dideoxy sequencing/KRAS StripAssay/pyrosequencing for detection of KRAS mutation in Chinese colorectal cancer (CRC) patients. METHODS: Formalin-fixed, paraffin-embedded (FFPE) samples with tumor cells >= 50% were collected from 100 Chinese CRC patients at Beijing Cancer Hospital. After the extraction of genome DNA from FFPE samples, fragments contained codons 12 and 13 of KRAS exon 2 were amplified by polymerase chain reaction and analyzed by dideoxy sequencing, the KRAS StripAssay and pyrosequencing. In addition, the sensitivities of the 3 methods were compared on serial dilutions (contents of mutant DNA: 100%, 50%, 20%, 15%, 10%, 5%, 1%, 0%) of A549 cell line DNA (carrying the codon 12 Gly>Ser mutation) into wild-type DNA (human normal intestinal mucosa). The results of dideoxy sequencing, the KRAS StripAssay and pyrosequencing were analyzed by Chromas Software, Collector for KRAS StripAssay and the pyrosequencing PyroMarkTM Q24 system, respectively. RESULTS: Among 100 patients, KRAS mutations were identified in 34%, 37% and 37% of patients by dideoxy sequencing, the KRAS StripAssay and pyrosequencing, respectively. The sensitivity was highest with the KRAS StripAssay (1%), followed by pyrosequencing (5%), and dideoxy sequencing was lowest (15%). Six different mutation types were found in this study with 3 main mutations Gly12Asp (GGT>GAT), Gly12Val (GGT>GTT) and Gly13Asp (GGC>GAC). Thirty-three patients were identified to have KRAS mutations by the 3 methods, and a total of 8 patients had conflicting results between 3 methods: 4 mutations not detected by dideoxy sequencing and the KRAS StripAssay were identified by pyrosequencing; 3 mutations not detected by dideoxy sequencing and pyrosequencing were identified by the KRAS StripAssay; and 1 mutation not detected by pyrosequencing was confirmed by dideoxy sequencing and the KRAS StripAssay. Among these discordant results, the results identified by dideoxy sequencing were consistent either with the KRAS StripAssay or with pyrosequencing, which indicated that the accuracy of dideoxy sequencing was high. CONCLUSION: Taking a worldwide view of reports and our results, dideoxy sequencing remains the most popular method because of its low cost and high accuracy. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:4858 / 4864
页数:7
相关论文
共 19 条
[1]
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
De Braud, F. G. ;
Volovat, C. ;
Nippgen, J. ;
Stroh, C. ;
Celik, I. ;
Koralewski, P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[2]
K-RAS MUTATION IN COLORECTAL-CANCER - RELATIONS TO PATIENT AGE, SEX AND TUMOR LOCATION [J].
BREIVIK, J ;
MELING, GI ;
SPURKLAND, A ;
ROGNUM, TO ;
GAUDERNACK, G .
BRITISH JOURNAL OF CANCER, 1994, 69 (02) :367-371
[3]
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[4]
DETECTION OF HIGH-INCIDENCE OF K-RAS ONCOGENES DURING HUMAN-COLON TUMORIGENESIS [J].
FORRESTER, K ;
ALMOGUERA, C ;
HAN, KY ;
GRIZZLE, WE ;
PERUCHO, M .
NATURE, 1987, 327 (6120) :298-303
[5]
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer [J].
Hebbar, Mohamed ;
Wacrenier, Agnes ;
Desauw, Christophe ;
Romano, Olivier ;
Cattan, Stephane ;
Triboulet, Jean-Pierre ;
Pruvot, Francois-Rene .
ANTI-CANCER DRUGS, 2006, 17 (07) :855-857
[6]
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer:: a combined analysis of 881 cases [J].
Huncharek, M ;
Muscat, J ;
Geschwind, JF .
CARCINOGENESIS, 1999, 20 (08) :1507-1510
[7]
Cetuximab for the treatment of colorectal cancer [J].
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Karapetis, Christos S. ;
Zalcberg, John R. ;
Tu, Dongsheng ;
Au, Heather-Jane ;
Berry, Scott R. ;
Krahn, Marianne ;
Price, Timothy ;
Simes, R. John ;
Tebbutt, Niall C. ;
van Hazel, Guy ;
Wierzbicki, Rafal ;
Langer, Christiane ;
Moore, Malcolm J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048
[8]
K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[9]
K-ras mutations in sporadic colorectal tumors in Israel -: Unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes [J].
Kislitsin, D ;
Lerner, A ;
Rennert, G ;
Lev, Z .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (05) :1073-1079
[10]
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].
Lievre, Astrid ;
Bachet, Jean-Baptiste ;
Boige, Valerie ;
Cayre, Anne ;
Le Corre, Delphine ;
Buc, Emmanuel ;
Ychou, Marc ;
Bouche, Olivier ;
Landi, Bruno ;
Louvet, Christophe ;
Andre, Thierry ;
Bibeau, Frederic ;
Diebold, Marie-Daniele ;
Rougier, Philippe ;
Ducreux, Michel ;
Tomasic, Gorana ;
Emile, Jean-Francois ;
Penault-Llorca, Frederique ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379